secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2022-09-09T23:59:59+00:00
Accession:  0001213900-22-055075
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma appoints Leeds Chow as CFO and Principal Accounting Officer effective Sept 4, 2022
--------------------------------------------------------------------------------

- Leeds Chow, 34, previously Controller since March 2021, appointed CFO and Principal Accounting Officer on Sept 4, 2022.
- Mr. Chow has over 12 years experience in audit and financing, including family office and Hong Kong IPO advisory roles.
- He holds a BA in Business Economics with Accounting Emphasis from the University of California, Santa Barbara.
- No departure of prior CFO was announced; the board determined the reappointment to be in the Company's best interests.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390022055075/0001213900-22-055075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390022055075/ea165554-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-055075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer